24/7 Market News Snapshot 13 January, 2025 – X4 Pharmaceuticals, Inc. Common Stock (NASDAQ:XFOR)

January 13, 2025

DENVER, Colo., 13 January, 2025 (247marketnews.com) – (NASDAQ:XFOR) are discussed in this article.
X4 Pharmaceuticals, Inc. has demonstrated a significant upward trajectory in the pre-market trading session, showing a rise of 15.42% to reach $0.658, buoyed by a robust trading volume of 5.11 million shares. This movement indicates substantial investor interest and suggests an environment conducive to potential further appreciation in stock value. Presently, resistance levels appear to be formed at recent highs, while support remains identifiable around the previous closing price of $0.570. Monitoring moving averages and relative strength index (RSI) trends will be essential to validate the strength of this rally, as continued enthusiasm could reflect an advantageous transformation in market sentiment towards X4.

In an exciting development, X4 Pharmaceuticals has announced an exclusive licensing and supply agreement with Norgine for mavorixafor, designed to enhance its presence in Europe, Australia, and New Zealand, pending appropriate regulatory approvals. This strategic partnership will yield an upfront payment of €28.5 million, alongside potential regulatory and commercial milestone payments totaling up to €226 million. Additionally, X4 stands to gain from a tiered royalty structure that could attain the mid-twenties percentage.

Mavorixafor, a selective CXCR4 receptor antagonist, is already marketed in the United States under the brand name XOLREMDI® for treating WHIM syndrome, a rare primary immunodeficiency disorder. With both the European Medicines Agency and the U.S. Food and Drug Administration officially designating mavorixafor as an Orphan Drug, X4 Pharmaceuticals is preparing to submit a Marketing Authorization Application shortly.

This collaboration marks a significant milestone for X4, reinforcing its mission to expand the accessibility of mavorixafor while simultaneously securing critical funding for its global Phase 3 clinical trial in chronic neutropenia. The alignment of goals between X4 Pharmaceuticals and Norgine exemplifies a commitment to addressing the ongoing needs of patients afflicted with rare immune disorders.

Related news for (XFOR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.